The FDA isn't happy with Orexigen ($OREX), which put out some early positive cardio data for obesity drug Contrave on Tuesday. The way the FDA sees it, the data were too early. In fact, it had already asked Orexigen for a second outcomes study because it had shared the info with too many people. But meanwhile, the new stats have changed some analysts' minds about Contrave's safety profile--something that could give it a leg up in a crowded market going forward. More